Title:sFlt-1: A Double Regulator in Angiogenesis-related Diseases
Volume: 27
Issue: 40
Author(s): Li Liao, Xingtao Zhao, Mengting Zhou, Ying Deng, Yunxia Li*Cheng Peng
Affiliation:
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu 611137,China
Keywords:
sFlt-1, preeclampsia, cardiovascular diseases, tumor, retinopathy, atherosclerosis.
Abstract:
Background: Vascular endothelial growth factor (VEGF) is a supergene family derived from a
platelet growth factor. It plays a pivotal role in regulating angiogenesis and lymphangiogenesis. sFlt-1 is a soluble
antagonist of VEGF with an essential effect of maintaining the balance of vascular growth. Recently, sFlt-1
has emerged as a new marker for early diagnosis and disease surveillance of angiogenesis-related diseases.
However, few comprehensive reviews focus on the relationship between sFlt-1 and related diseases despite that
many results have yielded.
Methods: In this review, we analyzed the relationship between sFlt-1 and angiogenesis-related diseases by
searching PubMed, Web of Science, and other databases, and summarized our current understanding of the role
of sFlt-1 in angiogenesis-related diseases.
Results: sFlt-1 is associated with pre-eclampsia, perinatal cardiomyopathy, diabetic nephropathy, hypertension,
tumor, atherosclerosis, and other diseases. The mechanisms of sFlt-1 that regulate those diseases are mainly associated
with the bioavailability of VEGF and vascular endothelial cell integrity.
Conclusion: From the summary article, sFlt-1 is a double regulator in angiogenesis-related diseases; too much
or too little may cause different diseases. Therefore, maintaining the stability of sFlt-1 content in the body is essential
to control the development of related diseases.
